Closed Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome
Efficacy of Closed-Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Julie C McCauley
- Phone Number: 585-554-7122
- Email: mccauley.julie@scrippshealth.org
Study Contact Backup
- Name: Roslyn M Kackman
- Phone Number: 858-554-7122
- Email: kackman.roslyn@scrippshealth.org
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- Scripps Clinic Torrey Pines
-
Contact:
- Julie C McCauley
- Phone Number: 585-554-7122
- Email: mccauley.julie@scrippshealth.org
-
Contact:
- Roslyn M Kackman
- Phone Number: 858-554-7122
- Email: kackman.roslyn@scrippshealth.org
-
Principal Investigator:
- David B Hiller, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years or older
- neuromodulation naive patients with unilateral CRPS type 1 or type 2 (defined by Budapest Criteria)
- pre-procedure psychological clearance
Exclusion Criteria:
- younger than 18 years
- prior neuromodulation including spinal cord stimulation
- prior dorsal root ganglion stimulation
- prior peripheral nervous system stimulation
- anatomical obstacles to dorsal column lead placement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Acute and Subacute Phases of CRPS
Participants diagnosed with acute and subacute phases of CRPS will be assigned to this group.
|
The closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
|
|
Experimental: Chronic Phase of CRPS
Participants diagnosed with chronic CRPS will be assigned to this group.
|
The closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Complex Regional Pain Syndrome Severity Scores
Time Frame: Baseline, 7 day trial period, 3 months, 6 months
|
(CRPS SS) This will be determined at baseline by the provider based on his diagnosis of the patient's condition, being acute and subacute or chronic.
This is based on the presence or absence of 16 clinically-assessed signs and symptoms, and complements the diagnostic criteria for CRPS.
A higher score indicates greater severity of the condition.
This will be followed up at the 7 day trial period, 3 months and 6 months post procedure by evaluation.
|
Baseline, 7 day trial period, 3 months, 6 months
|
|
Change in Target Activation Amplitude Levels by the Spinal Cord Stimulation Device
Time Frame: 7 day trial period, 3 months, and 6 months.
|
Spinal cord stimulation device parameters will be collected to determine if a lower voltage is required to treat acute phase of complex regional pain syndrome as compared to later phases.
This will be conducted at follow up visits and analyzed by the medical device representative.
The data will be pulled and analyzed to determine the activation point for each patient.
This will be captured at the 7 day trial period, 3 months, and 6 months.
|
7 day trial period, 3 months, and 6 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Prolactin Levels
Time Frame: Baseline, 7 day trial period, and 3 months
|
We plan to include a physiological marker of pain response by assessing serum prolactin levels, which are linked to dopamine levels in the brain.
We will use prolactin as a convenient marker of abnormal dopamine levels due to chronic pain and the response to spinal cord stimulation treatment as an objective quantifiable metric of success with treatment.
We will collect this via blood draw at our lab at baseline, at the 7 day trial period, and 3 months.
|
Baseline, 7 day trial period, and 3 months
|
|
Visual Analogue Pain Scale
Time Frame: Baseline, 7 day trial period, 3 months, and 6 months
|
(VAS) This will be used to determine the pain intensity the patient is experiencing.
It will be on a scale from 0-10, 0 being no pain and 10 being the worst pain.
|
Baseline, 7 day trial period, 3 months, and 6 months
|
|
Quality of Life Questionnaire
Time Frame: Baseline, 7 day trial period, 3 months, and 6 months
|
(EQ-5D-5L) Used to capture quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
A lower score would indicate a severe score and the patient has a low quality of life.
The patient also rates how good or bad their health is on a scale of 0-100, 100 being the best health and 0 being the worst health they could imagine.
|
Baseline, 7 day trial period, 3 months, and 6 months
|
|
Patient Reported Outcomes Measurement Information System-29 v 2.1
Time Frame: Baseline, 7 day trial period, 3 months, and 6 months
|
(PROMIS-29v2.1)
Used to assess pain intensity using a single 0-10 numeric rating item and seven health domains: physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance.
|
Baseline, 7 day trial period, 3 months, and 6 months
|
|
General Anxiety Disorder-7
Time Frame: Baseline, 7 day trial period, 3 months and 6 months.
|
(GAD-7) Used for the screening and severity measuring of generalized anxiety disorder.
It consists of seven items the patients rate based on their experiences over the past two weeks.
Each item is scored from 0 (none) to 3 (every day).
The cumulative score, ranging from 0-21, indicates the severity of GAD symptoms, with higher scores corresponding to greater anxiety levels.
|
Baseline, 7 day trial period, 3 months and 6 months.
|
|
Patient Health Questionnaire-9
Time Frame: Baseline, 7 day trial period, 3 months, 6 months
|
(PHQ-9) Used for screening and measuring the severity of depression.
A higher score would indicate the patient has a worse outcome.
|
Baseline, 7 day trial period, 3 months, 6 months
|
|
Short-Form McGill Pain Questionnaire-2
Time Frame: Baseline, 7 day trial period, 3 months, 6 months
|
(SF-MPQ-2) Used to rate the intensity of each type of pain and related symptoms.
A higher score means the patient has a worse outcome.
They rate their pain and symptoms on a scale of 0-10, with a 0 being no pain and 10 being the worst pain.
|
Baseline, 7 day trial period, 3 months, 6 months
|
|
Pain Catastrophizing Scale
Time Frame: Baseline, 7 day trial period, 3 months, 6 months
|
(PCS) Used to assess catastrophic thinking related to pain among adults with or without chronic pain.
A higher score would mean the patient has a worse outcome.
|
Baseline, 7 day trial period, 3 months, 6 months
|
|
Patient Global Impression of Change
Time Frame: 7 day trial period, 3 months and 6 months
|
(PGIC) Used to measure the patient's belief about the effectiveness of the treatment.
A higher score would reflect the patient believes the treatment is not effective and they have been doing much worse.
|
7 day trial period, 3 months and 6 months
|
|
Amount of Pain Medication Consumed by Patient
Time Frame: Baseline, 7 day trial period, 3 months and 6 months
|
Used to track amount of pain medication taken by the patient on a daily basis or what they are taking and when they are taking it.
|
Baseline, 7 day trial period, 3 months and 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David B Hiller, MD, Physician
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 24-8347
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.